More tools:
Markets
·
Screener
·
Research
·
Chat
ODYSSEY THERAPEUTICS INC (ODTX) Financial Statements
ODYSSEY THERAPEUTICS INC
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG0135WDLZ7
US
26.22
▲ 7.15 (37.49%)
As of 2026-09-09
1M
6M
1Y
Valuation
Market Cap
$1.3B
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
—
EBITDA
—
Diluted EPS (TTM)
—
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
19.07
Day's Range
17.95 – 19.49
52-Week Range
15.35 – 20.30
Volume
1.6M
Avg Volume
471.4K
Share Statistics
Shares Outstanding
48.1M
Employees
—
Exchange
US
Listed
—
Share count as of August 3, 2026
View
Income Statement
Balance Sheet
Cash Flow
Key Metrics
Valuation
Comparable Companies
Notes & Facts
DCF Model
Earnings Calls
Guidance
Presentations
Detail
Standard
Detailed
Period
Annual
Quarterly
TTM
Loading Income Statement…
Key questions about ODYSSEY THERAPEUTICS INC (ODTX)
What is ODYSSEY THERAPEUTICS INC's Market Cap?
ODYSSEY THERAPEUTICS INC's Market Cap is $1.3B, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Subscribe
Income Statement
(in thousands of USD, except per-share data)
Source: Akyla.ai
Line Item
Jun 30, 2026
Mar 31, 2026
Jun 30, 2025
Mar 31, 2025
Collaboration revenue
0.0
0.0
Operating expenses:
Research and development
36,226.0
32,321.0
General and administrative
10,511.0
7,350.0
Change in fair value of contingent consideration
8,733.0
109.0
Total operating expenses
55,470.0
39,780.0
% of revenue
—
—
Operating loss
(55,470.0)
(39,780.0)
% of revenue
—
—
Other income (expense), net:
Interest income
2,832.0
1,708.0
Interest expense
(20.0)
(10.0)
Other expense, net
(138.0)
(117.0)
Total other income, net
2,674.0
1,581.0
Loss before income taxes
(52,796.0)
(38,199.0)
Income tax provision
(8.0)
63.0
Net loss
(52,788.0)
(38,262.0)
% of revenue
—
—
Net loss attributable to common stockholders (see Note 15)
(52,788.0)
(38,262.0)
Net loss per share attributable to common stockholders, basic
(1.74)
(6.77)
Net loss per share attributable to common stockholders, diluted
(1.74)
(6.77)